As the COVID-19 pandemic has shown, it is critical for pharmaceutical companies to find and engage digital activators to reach more healthcare professionals, earlier and quicker. This can steepen the product adoption curve.
Using data science to improve healthcare outcomes, Swiss AI platform PeakData has raised €12.1 million in Series A funding to identify and collate the most relevant and impactful healthcare professionals (HCPs) for pharmaceutical companies. The round was led by AlbionVC and backed by Octopus Ventures and Heal Capital.
According to the company, the Series A funding follows rapid 6x growth over 2021, with the PeakData platform now being used by over half of Europe’s largest pharmaceutical companies.
Founded in 2018 by Patrick De Boer and Michael Feldman, the platform uses AI algorithms to rank HCPs in terms of their digital impact, influence and relevance to their target market. It uses dynamic data to observe changes in HCP status over time. Thus, the startup enables pharmaceutical companies to enhance the depth and breadth of their customer base and learn more about HCPs that are most relevant to their target market. This, in turn, enables patients to benefit from innovative new medicines much sooner.
Patrick De Boer, co-founder of PeakData said: “We started PeakData after a dawning realisation that AI could help provide better patient outcomes. To ensure healthcare professionals are aware of the latest medicines, pharmaceutical companies must be provided with the latest data about them and their key focus areas. PeakData is filling a key gap in how our customers receive and analyse this data to improve the conversations they are having with a much wider variety of HCPs in their area.”
Christoph Ruedig, partner at AlbionVC said: “Finding the right therapeutic experts and healthcare professionals for their medicines is massively important for pharmaceutical companies and with PeakData they can now reach global, national, and local medical professionals who shape clinical decision-making.”